ProQR Therapeutics N.V.
NASDAQ:PRQRBiotechnology
+$0.21 today
- Market cap
- $155.23M
- Beta
- 0.06
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.43
Volume 0.88M
Average 0.62M
PRQR Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
ProQR Therapeutics N.V.NASDAQ: PRQR
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow declines year over year
Q1 FY2026 investing cash flow of €166.7K (cash outflow) fell 25.6% year over year, ahead of the -107.1% change in trailing-twelve-month investing cash flow. Sequentially, it fell 67.9% from the prior quarter. Over 3 fiscal years it compounded at +11.8% a year.
Context
- Investing cash flow amounted to 6.4% of revenue in FY2025, down 15.1 pp from a year earlier.
- Investing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -25.6% holds above the trailing-twelve-month pace of -107.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
EUR · from the cash flow
- Latest · FY2025
- (979.74K) EUR
- Year-over-year change
- +75.9%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (979.74K) | +75.9% |
| FY2024 | 2024-12-31 | (4.07M) | -195.2% |
| FY2023 | 2023-12-31 | 4.28M | +709.4% |
| FY2022 | 2022-12-31 | (702K) | -65.2% |
| FY2021 | 2021-12-31 | (425K) | — |
Investing Cash Flow vs competitors
How PRQR compares with its peers on the latest reported figures
- Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -107.1% is the lowest of 11, against a peer median of -1.0%.
- Investing cash flow amounts to 7.1% of revenue for PRQR, versus a peer median of 122.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $139.01M USD | +382.8% | — | 2422.7% | |
| LTM Mar 2026 | $82.35M USD | -63.1% | +6.7% | 212.8% | |
| LTM Mar 2026 | $81.05M USD | -2.1% | — | — | |
| LTM Mar 2026 | $71.19M USD | +59.3% | +23.9% | 32.7% | |
| LTM Mar 2026 | $59.8M USD | +0.1% | -3.4% | — | |
| FY2025 | A$38.53M AUD | +83.3% | +1089.2% | 764.0% | |
| LTM Mar 2026 | $9.03M USD | +188.3% | — | — | |
| LTM Mar 2026 | €955.79K EUR | -107.1% | +11.8% | 7.1% | |
ZURAZura Bio Limited | LTM Mar 2026 | $77K USD | -34.2% | -78.9% | — |
| LTM Mar 2026 | $59.66K USD | -89.1% | -69.0% | 0.1% | |
| LTM Mar 2026 | $3.04K USD | -99.0% | — | 0.6% | |
| Peer median (excluding PRQR) | — | -1.0% | +1.6% | 122.8% | |
Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (60.8M) | (64.2M) | (27.74M) | (27.76M) | (40.52M) |
| Depreciation & Amortization | 2.33M | 2.52M | 2.51M | 2.76M | 2.6M |
| Deferred Income Tax | 117K | 96K | (78K) | (197K) | 0 |
| Stock-Based Compensation | 6.22M | 2.87M | 3.11M | 2.54M | 0 |
| Change in Working Capital | 25.01M | (4.99M) | 48.96M | (13.26M) | (16.73M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 25.01M | (4.99M) | 48.96M | (13.26M) | (16.73M) |
| Other Non-Cash Items | 1.11M | (4.8M) | (5.21M) | (474K) | 3.94M |
| Operating Cash Flow | (26.01M) | (68.51M) | 21.55M | (36.39M) | (50.71M) |
| Capital Expenditures | (484K) | (708K) | (1.37M) | (1.42M) | (979.75K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (17M) | 0 |
| Sales of Investments | 0 | 0 | 0 | 17M | 0 |
| Other Investing Activities | 59K | 6K | 5.65M | (2.66M) | 0 |
| Investing Cash Flow | (425K) | (702K) | 4.28M | (4.07M) | (979.74K) |
| Debt Repayment | 26.84M | (45.05M) | (2.63M) | (1.58M) | (1.91M) |
| Common Stock Issued | 108.48M | 14.12M | 0 | 71.64M | 66.28K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.52M | 34K | 354K | 223K | 75.19K |
| Financing Cash Flow | 136.83M | (30.89M) | (2.28M) | 70.28M | (1.76M) |
| Effect of Forex Changes | 1.29M | 7.35M | 599K | 673K | 14.15M |
| Net Change in Cash | 111.69M | (92.75M) | 24.15M | 30.48M | (39.3M) |
| Free Cash Flow | (26.5M) | (69.22M) | 20.18M | (37.81M) | (51.69M) |
ProQR Therapeutics N.V.
NASDAQ:PRQR
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.